Cosciens Biopharma Stock Performance
| CSCI Stock | 2.92 0.21 6.71% |
The firm shows a Beta (market volatility) of -0.13, which signifies not very significant fluctuations relative to the market. As returns on the market increase, returns on owning COSCIENS Biopharma are expected to decrease at a much lower rate. During the bear market, COSCIENS Biopharma is likely to outperform the market. At this point, COSCIENS Biopharma has a negative expected return of -0.33%. Please make sure to confirm COSCIENS Biopharma's skewness, as well as the relationship between the rate of daily change and period momentum indicator , to decide if COSCIENS Biopharma performance from the past will be repeated at future time.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days COSCIENS Biopharma has generated negative risk-adjusted returns adding no value to investors with long positions. Despite unsteady performance in the last few months, the Stock's fundamental indicators remain fairly strong which may send shares a bit higher in January 2025. The recent confusion may also be a sign of long-lasting up-swing for the firm traders. ...more
Actual Historical Performance (%)
One Day Return 4.33 | Five Day Return 2.29 | Year To Date Return (47.83) | Ten Year Return (47.83) | All Time Return (47.83) |
Last Split Factor 1:4 | Last Split Date 2024-05-03 |
1 | StockNews.com Begins Coverage on Aeterna Zentaris | 09/16/2024 |
2 | COSCIENS Biopharma Welcomes New Board Director - TipRanks | 10/01/2024 |
3 | Aeterna Zentaris Coverage Initiated at StockNews.com | 10/17/2024 |
4 | COSCIENS Biopharma Inc. Reports Third Quarter 2024 Financial Results and Provides Update on Advancements with Merger Integration Process and Ongoing Development... | 11/12/2024 |
| Begin Period Cash Flow | 10.4 M |
COSCIENS |
COSCIENS Biopharma Relative Risk vs. Return Landscape
If you would invest 397.00 in COSCIENS Biopharma on September 3, 2024 and sell it today you would lose (84.00) from holding COSCIENS Biopharma or give up 21.16% of portfolio value over 90 days. COSCIENS Biopharma is currently does not generate positive expected returns and assumes 2.9612% risk (volatility on return distribution) over the 90 days horizon. In different words, 26% of stocks are less volatile than COSCIENS, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
COSCIENS Biopharma Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for COSCIENS Biopharma's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as COSCIENS Biopharma, and traders can use it to determine the average amount a COSCIENS Biopharma's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1105
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | CSCI |
Estimated Market Risk
| 2.96 actual daily | 26 74% of assets are more volatile |
Expected Return
| -0.33 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.11 actual daily | 0 Most of other assets perform better |
Based on monthly moving average COSCIENS Biopharma is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of COSCIENS Biopharma by adding COSCIENS Biopharma to a well-diversified portfolio.
COSCIENS Biopharma Fundamentals Growth
COSCIENS Stock prices reflect investors' perceptions of the future prospects and financial health of COSCIENS Biopharma, and COSCIENS Biopharma fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on COSCIENS Stock performance.
| Return On Equity | -0.66 | ||||
| Return On Asset | -0.23 | ||||
| Operating Margin | (1.61) % | ||||
| Current Valuation | (13.04 M) | ||||
| Shares Outstanding | 3.12 M | ||||
| Price To Book | 0.49 X | ||||
| Price To Sales | 2.66 X | ||||
| Revenue | 7.26 M | ||||
| EBITDA | (17.99 M) | ||||
| Net Income | (3.55 M) | ||||
| Total Debt | 3.59 M | ||||
| Book Value Per Share | 8.57 X | ||||
| Cash Flow From Operations | (2.73 M) | ||||
| Earnings Per Share | (2.69) X | ||||
| Total Asset | 31.45 M | ||||
| Retained Earnings | 6.17 M | ||||
About COSCIENS Biopharma Performance
By evaluating COSCIENS Biopharma's fundamental ratios, stakeholders can gain valuable insights into COSCIENS Biopharma's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if COSCIENS Biopharma has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if COSCIENS Biopharma has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
COSCIENS Biopharma is entity of United States. It is traded as Stock on NASDAQ exchange.Things to note about COSCIENS Biopharma performance evaluation
Checking the ongoing alerts about COSCIENS Biopharma for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for COSCIENS Biopharma help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| COSCIENS Biopharma generated a negative expected return over the last 90 days | |
| COSCIENS Biopharma has high likelihood to experience some financial distress in the next 2 years | |
| COSCIENS Biopharma was previously known as Aeterna Zentaris and was traded on NASDAQ Exchange under the symbol AEZS. | |
| The company reported the previous year's revenue of 7.26 M. Net Loss for the year was (3.55 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| COSCIENS Biopharma generates negative cash flow from operations | |
| Latest headline from globenewswire.com: COSCIENS Biopharma Inc. Reports Third Quarter 2024 Financial Results and Provides Update on Advancements with Merger Integration Process and Ongoing Development Programs |
- Analyzing COSCIENS Biopharma's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether COSCIENS Biopharma's stock is overvalued or undervalued compared to its peers.
- Examining COSCIENS Biopharma's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating COSCIENS Biopharma's management team can have a significant impact on its success or failure. Reviewing the track record and experience of COSCIENS Biopharma's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of COSCIENS Biopharma's stock. These opinions can provide insight into COSCIENS Biopharma's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for COSCIENS Stock analysis
When running COSCIENS Biopharma's price analysis, check to measure COSCIENS Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy COSCIENS Biopharma is operating at the current time. Most of COSCIENS Biopharma's value examination focuses on studying past and present price action to predict the probability of COSCIENS Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move COSCIENS Biopharma's price. Additionally, you may evaluate how the addition of COSCIENS Biopharma to your portfolios can decrease your overall portfolio volatility.
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets |